NASDAQ:LIFE aTyr Pharma (LIFE) Stock Forecast, Price & News $1.58 -0.01 (-0.63%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$1.58▼$1.6250-Day Range$1.55▼$2.0152-Week Range$1.53▼$3.07Volume98,578 shsAverage Volume183,907 shsMarket Capitalization$90.14 millionP/E RatioN/ADividend YieldN/APrice Target$20.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media aTyr Pharma MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside1,213.3% Upside$20.75 Price TargetShort InterestHealthy0.72% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.01) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector278th out of 970 stocksBiological Products, Except Diagnostic Industry44th out of 157 stocks 3.4 Analyst's Opinion Consensus RatingaTyr Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.75, aTyr Pharma has a forecasted upside of 1,213.3% from its current price of $1.58.Amount of Analyst CoverageaTyr Pharma has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.72% of the outstanding shares of aTyr Pharma have been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in aTyr Pharma has recently decreased by 5.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LIFE. Previous Next 2.6 News and Social Media Coverage News SentimentaTyr Pharma has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for aTyr Pharma this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for LIFE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.14% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions62.53% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for aTyr Pharma are expected to decrease in the coming year, from ($1.01) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioaTyr Pharma has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About aTyr Pharma (NASDAQ:LIFE) StockaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.Read More LIFE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIFE Stock News HeadlinesSeptember 28, 2023 | markets.businessinsider.comBuy Rating for aTyr Pharma: Promising Developments in Efzofitimod Clinical Trials and Potential Expansion OpportunitiesSeptember 26, 2023 | markets.businessinsider.comaTyr Pharma (LIFE) Gets a Buy from Piper SandlerSeptember 30, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 25, 2023 | americanbankingnews.comReviewing AlloVir (NASDAQ:ALVR) and aTyr Pharma (NASDAQ:LIFE)September 25, 2023 | americanbankingnews.comFY2025 EPS Estimates for aTyr Pharma, Inc. Raised by Analyst (NASDAQ:LIFE)September 23, 2023 | americanbankingnews.comaTyr Pharma (NASDAQ:LIFE) Stock Rating Reaffirmed by HC WainwrightSeptember 23, 2023 | americanbankingnews.comaTyr Pharma, Inc. (NASDAQ:LIFE) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), Genfit SA (GNFT) and Boston Scientific (BSX)September 30, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 11, 2023 | finance.yahoo.comaTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported OutcomesAugust 30, 2023 | finance.yahoo.comDown -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)August 30, 2023 | finance.yahoo.comWe're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash WiselyAugust 24, 2023 | finance.yahoo.comaTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 11, 2023 | markets.businessinsider.comJonesTrading Sticks to Its Buy Rating for aTyr Pharma (LIFE)August 9, 2023 | finance.yahoo.comaTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate UpdateAugust 2, 2023 | msn.comAtyr Pharma (LIFE) Price Target Increased by 8.21% to 21.76July 20, 2023 | finance.yahoo.comaTyr Pharma, Inc. (NASDAQ:LIFE) is a favorite amongst institutional investors who own 56%July 5, 2023 | msn.comOppenheimer Downgrades Atyr Pharma (LIFE)July 5, 2023 | msn.comaTyr Pharma's Cash Runway Secured till 2026, Despite Lack of Material Catalysts: Oppenheimer AnalystJune 28, 2023 | markets.businessinsider.com7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023June 22, 2023 | finance.yahoo.comEuropean Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic SclerosisJune 20, 2023 | finance.yahoo.comaTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) ConferenceJune 6, 2023 | finance.yahoo.comaTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)May 25, 2023 | finance.yahoo.comaTyr Pharma to Present at the 2023 Jefferies Healthcare ConferenceMay 23, 2023 | nasdaq.comHC Wainwright & Co. Reiterates Atyr Pharma (LIFE) Buy RecommendationMay 23, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for aTyr PharmaMay 23, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for aTyr Pharma (LIFE)See More Headlines Receive LIFE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LIFE Company Calendar Last Earnings8/09/2023Today9/30/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:LIFE CUSIP53217V10 CIK1339970 Webwww.atyrpharma.com Phone(858) 731-8389Fax858-731-8394Employees65Year Founded2005Price Target and Rating Average Stock Price Forecast$20.75 High Stock Price Forecast$35.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+1,213.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,340,000.00 Net MarginsN/A Pretax Margin-433.87% Return on Equity-49.51% Return on Assets-39.06% Debt Debt-to-Equity Ratio0.01 Current Ratio9.25 Quick Ratio9.25 Sales & Book Value Annual Sales$10.39 million Price / Sales8.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.42 per share Price / Book0.65Miscellaneous Outstanding Shares57,050,000Free Float55,255,000Market Cap$90.14 million OptionableOptionable Beta1.26 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Sanjay S. Shukla M.D. (Age 51)M.S., Pres, CEO & Director Comp: $795.48kMs. Jill M. Broadfoot (Age 61)Chief Financial Officer Comp: $556.62kMs. Nancy E. Denyes Krueger (Age 55)Gen. Counsel & Corp. Sec. Comp: $532.13kXiang-Lei Yang Ph.D.FounderMs. Ashlee DunstonDirector of Investor Relations & Corp. CommunicationsMr. Peter VilligerVP of Corp. Devel.Ms. Danielle CampbellVP of Human ResourceDr. Leslie Nangle Ph.D.VP of ResearchDr. Ying J. Buechler Ph.D.Exec. Director of Biologics Devel. & ManufacturingDr. David J. King (Age 64)Scientific Consultant More ExecutivesKey CompetitorsCellectisNASDAQ:CLLSC4 TherapeuticsNASDAQ:CCCCCidara TherapeuticsNASDAQ:CDTXBioAtlaNASDAQ:BCABCompugenNASDAQ:CGENView All CompetitorsInsiders & InstitutionsXTX Topco LtdBought 170,425 shares on 8/15/2023Ownership: 0.299%Royal Bank of CanadaBought 7,356 shares on 8/15/2023Ownership: 0.148%Boothbay Fund Management LLCSold 44,000 shares on 8/15/2023Ownership: 0.063%Citadel Advisors LLCBought 10,300 shares on 8/15/2023Ownership: 0.000%Two Sigma Securities LLCBought 12,001 shares on 8/14/2023Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions LIFE Stock - Frequently Asked Questions Should I buy or sell aTyr Pharma stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LIFE shares. View LIFE analyst ratings or view top-rated stocks. What is aTyr Pharma's stock price forecast for 2023? 6 Wall Street research analysts have issued 1 year price objectives for aTyr Pharma's shares. Their LIFE share price forecasts range from $9.00 to $35.00. On average, they predict the company's stock price to reach $20.75 in the next twelve months. This suggests a possible upside of 1,213.3% from the stock's current price. View analysts price targets for LIFE or view top-rated stocks among Wall Street analysts. How have LIFE shares performed in 2023? aTyr Pharma's stock was trading at $2.19 at the beginning of 2023. Since then, LIFE shares have decreased by 27.9% and is now trading at $1.58. View the best growth stocks for 2023 here. Are investors shorting aTyr Pharma? aTyr Pharma saw a decrease in short interest in September. As of September 15th, there was short interest totaling 411,800 shares, a decrease of 5.9% from the August 31st total of 437,400 shares. Based on an average daily trading volume, of 256,600 shares, the short-interest ratio is presently 1.6 days. View aTyr Pharma's Short Interest. When is aTyr Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our LIFE earnings forecast. How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:LIFE) announced its quarterly earnings results on Wednesday, August, 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. When did aTyr Pharma's stock split? aTyr Pharma's stock reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO? 3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). When did aTyr Pharma IPO? (LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers. What is aTyr Pharma's stock symbol? aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE." How do I buy shares of aTyr Pharma? Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is aTyr Pharma's stock price today? One share of LIFE stock can currently be purchased for approximately $1.58. How much money does aTyr Pharma make? aTyr Pharma (NASDAQ:LIFE) has a market capitalization of $90.14 million and generates $10.39 million in revenue each year. The biotechnology company earns $-45,340,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. How can I contact aTyr Pharma? aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The official website for the company is www.atyrpharma.com. The biotechnology company can be reached via phone at (858) 731-8389, via email at investorrelations@atyrpharma.com, or via fax at 858-731-8394. This page (NASDAQ:LIFE) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.